Latest News
Immedica gets UAE approval for Zepzelca maintenance treatment
28 November 2025 - Swedish pharmaceutical company Immedica Pharma AB said on Friday that the Zepzelca (lurbinectedin) + Tecentriq (atezolizumab) maintenance regimen is now approved by the Emirates Drug Establishment for adults in the United Arab Emir...
HEALTH Magazine's Beyond Pink Event Brings Experts and Survivors Together to Spotlight Women's Health in the UAE
28 November 2025 - Beyond Pink welcomed healthcare professionals, cancer survivors and community figures for an evening focused on wellness, awareness and preventative care for women. Taking place at the Grand Hyatt Dubai, the event began with a netw...
Imugene Ltd enters co-development collaboration with JW Therapeutics (Shanghai)
28 November 2025 - Imugene Ltd (ASX:IMU), an Australian clinical-stage immuno-oncology company, announced on Thursday that it has entered a co-development collaboration with JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a Chinese biotechnology com...
Sichuan Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy clinical study results published in Annals of Oncology
28 November 2025 - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKEX: 6990), a China-based holding subsidiary of Kelun Pharmaceutical (002422.SZ), announced on Thursday that the journal of Annals of Oncology (Impact Factor: 65.4) has published ...
Kedrion's investigational treatment for Congenital Aceruloplasminemia receives European Orphan Drug Designation
28 November 2025 - Kedrion Biopharma, an Italy-based biopharmaceutical company, announced on Thursday that it has received Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its investigational treatment for Congenital Acerulo...